Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Collagen + alginate is a combination biomaterial used in advanced wound care for the management of chronic and acute wounds. It typically consists of a freeze-dried (lyophilized) matrix of bovine-derived Type I collagen and calcium alginate. The collagen component serves a dual purpose: it acts as a sacrificial substrate to bind and inactivate excess matrix metalloproteinases (MMPs) that are often elevated in chronic wounds and impede healing, and it provides a structural scaffold that promotes the migration and attachment of fibroblasts and keratinocytes. The alginate component is highly absorbent; upon contact with wound exudate, it interacts with the fluid to form a hydrophilic gel. This gel maintains a moist wound environment, facilitates autolytic debridement, and allows for atraumatic dressing changes by preventing the dressing from adhering to the wound bed. This combination is widely indicated for pressure ulcers, diabetic foot ulcers, venous leg ulcers, and surgical sites.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on collagen + alginate.